非小细胞肺癌免疫治疗疗效预测新指标——LIPI评分系统

国际肿瘤学杂志››2020,Vol. 47››Issue (5): 301-303.doi:10.3760/cma.j.cn371439-20190926-00023

非小细胞肺癌免疫治疗疗效预测新指标——LIPI评分系统

张爱霞(), 孙亚红

betway必威登陆网址第三附属医院(betway.com 附属医院)肿瘤内二科,济南 250031

收稿日期:2019-09-26修回日期:2020-01-20出版日期:2020-05-08发布日期:2020-07-02
通讯作者:张爱霞 E-mail:doctorzhangax@163.com
基金资助:
betway.com 医药卫生科技创新工程

A new predictor of the efficacy of immunotherapy for non-small cell lung cancer—lung immune prognostic index (LIPI)

Zhang Aixia(), Sun Yahong

Second Department of Oncology, Third Affiliated Hospital of Shandong First Medical University (Affiliated Hospital of Shandong Academy of Medical Sciences), Jinan 250031, China

Received:2019-09-26Revised:2020-01-20Online:2020-05-08Published:2020-07-02
Contact:Zhang Aixia E-mail:doctorzhangax@163.com
Supported by:
Innovation Project of Shandong Academy of Medical Sciences

摘要/Abstract

摘要：

免疫检查点抑制剂已被证实可显著提高多种恶性肿瘤患者的生存率,因此需要寻找有效的疗效预测指标来指导免疫治疗。肺免疫预后指数(LIPI)是近期发展起来的预测非小细胞肺癌免疫治疗疗效的新指标。基线LIPI能够识别免疫治疗潜在获益人群,是一种方便有效的预后预测指标。

关键词:癌,非小细胞肺,预后,免疫检查点抑制剂,肺免疫预后指数

Abstract:

Immune checkpoint inhibitors have demonstrated the ability to significantly improve survival across a range of cancers. So predictive markers are required to guide treatment decisions. The lung immune prognostic index (LIPI) is recently developed to predict immune checkpoint inhibitors (ICIs) treatment outcomes for non-small cell lung cancer. The pre-treatment LIPI is a convenient prognostic marker able to idenjpgy ICIs-treated patient groups with significantly different survival and response outcomes.

Key words:Carcinoma,non-small-cell lung,Prognosis,Immune checkpoint inhibitor,Lung immune prognostic index

张爱霞, 孙亚红. 非小细胞肺癌免疫治疗疗效预测新指标——LIPI评分系统[J]. 国际肿瘤学杂志, 2020, 47(5): 301-303.

Zhang Aixia, Sun Yahong. A new predictor of the efficacy of immunotherapy for non-small cell lung cancer—lung immune prognostic index (LIPI)[J]. Journal of International Oncology, 2020, 47(5): 301-303.

参考文献20

[1]	Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade[J]. Science, 2018,359(6382):1350-1355. DOI: 10.1126/science.aar4060. doi:10.1126/science.aar4060pmid:29567705
[2]	Park YJ, Kuen DS, Chung Y. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance[J]. Exp Mol Med, 2018,50(8):109. DOI: 10.1038/s12276-018-0130-1. doi:10.1038/s12276-018-0130-1pmid:30135516
[3]	Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015,373(17):1627-1639. DOI: 10.1056/NEJMoa1507643. doi:10.1056/NEJMoa1507643pmid:26412456
[4]	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015,373(2):123-135. DOI: 10.1056/NEJMoa1504627. doi:10.1056/NEJMoa1504627pmid:26028407
[5]	Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial[J]. Lancet, 2016,387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. doi:10.1016/S0140-6736(15)01281-7pmid:26712084
[6]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016,375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. doi:10.1056/NEJMoa1606774pmid:27718847
[7]	Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicenter randomised controlled trial[J]. Lancet, 2017,389(10066):255-265. DOI: 10.1016/S0140-6736(16)32517-X. doi:10.1016/S0140-6736(16)32517-Xpmid:27979383
[8]	Hopkins AM, Rowland A, Kichenadasse G, et al. Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers[J]. Br J Cancer, 2017,117(7):913-920. DOI: 10.1038/bjc.2017.274. doi:10.1038/bjc.2017.274pmid:28950287
[9]	Prelaj A, Tay R, Ferrara R, et al. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer[J]. Eur J Cancer, 2019,106:144-159. DOI: 10.1016/j.ejca.2018.11.002. doi:10.1016/j.ejca.2018.11.002pmid:30528799
[10]	Peters S, Gettinger S, Johnson ML, et al. Phase Ⅱ trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)[J]. J Clin Oncol, 2017,35(24):2781-2789. DOI: 10.1200/JCO.2016.71.9476. doi:10.1200/JCO.2016.71.9476pmid:28609226
[11]	Spigel DR, Chaft JE, Gettinger S, et al. FIR: efficacy, safety, and biomarker analysis of a phase Ⅱ open-label study of atezolizumab in PD-L1-selected patients with NSCLC[J]. J Thorac Oncol, 2018,13(11):1733-1742. DOI: 10.1016/j.jtho.2018.05.004. doi:10.1016/j.jtho.2018.05.004pmid:29775807
[12]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011,144(5):646-674. DOI: 10.1016/j.cell.2011.02.013. doi:10.1016/j.cell.2011.02.013
[13]	Zhu L, Li X, Shen Y, et al. A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer[J]. Onco Targets Ther, 2016,9:4879-4886. DOI: 10.2147/OTT.S107279. doi:10.2147/OTT.S107279pmid:27540301
[14]	Laird BJ, Fallon M, Hjermstad MJ, et al. Qualityof life in patients with advanced cancer: differential association with performance status and systemic inflammatory response[J]. J Clin Oncol, 2016,34(23):2769-2775. DOI: 10.1200/JCO.2015.65.7742. doi:10.1200/JCO.2015.65.7742pmid:27354484
[15]	McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer[J]. Cancer Treat Rev, 2013,39(5):534-540. DOI: 10.1016/j.ctrv.2012.08.003. doi:10.1016/j.ctrv.2012.08.003pmid:22995477
[16]	Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer[J]. JAMA Oncol, 2018,4(3):351-357. DOI: 10.1001/jamaoncol.2017.4771. doi:10.1001/jamaoncol.2017.4771pmid:29327044
[17]	Sorich MJ, Rowland A, Karapetis CS, et al. Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials[J]. J Thorac Oncol, 2019,14(8):1440-1446. DOI: 10.1016/j.jtho.2019.04.006. doi:10.1016/j.jtho.2019.04.006pmid:30999110
[18]	Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016,387(10030):1837-1846. DOI: 10.1016/S0140-6736(16)00587-0. doi:10.1016/S0140-6736(16)00587-0pmid:26970723
[19]	Kazandjian D, Gong Y, Keegan P, et al. Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small-cell lung cancer[J]. JAMA Oncol, 2019,5(10):1481-1485. DOI: 10.1001/jamaoncol.2019.1747. doi:10.1001/jamaoncol.2019.1747
[20]	Kim YJ, Kim CH, Lee SH, et al. Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced NSCLC treated with immune checkpoint inhibitor[J]. J Thorac Oncol, 2019,14(9):1608-1618. DOI: 10.1016/j.jtho.2019.05.033. doi:10.1016/j.jtho.2019.05.033pmid:31195179